GLP-1 receptor agonists work by enhancing insulin section, reducing glucagon release and improving glucose control and satiety. They include Liraglutide (Saxenda, Victoza), Dulaglutide (Trulicity) and Semaglutide (Wegovy, Ozempic, Rybelsus). Tirzapatide (Mounjaro) is both a GLP-1 receptor agonist and GIP analog. The GLP-1 receptor agonists currently licensed for weight management in the UK are Saxenda, Wegovy and Mounjaro, while Victoza, Trulicity, Ozempic and Rybelsus are licensed for use in the management of type 2 diabetes.
It is estimated that there may be as many as 500,000 private users of GLP-1 agonists for weight loss in the UK. Social media reporting and anecdotal evidence from health care professionals suggests that there are significant numbers of women who may be becoming pregnant on GLP-1 receptor agonists. However, there is currently very little guidance on how to best manage these women. We would like to evaluate how experienced healthcare professionals are currently caring for women who have taken GLP-1 agonists in the periconception period and whether they have any concerns about potential adverse effects.
Researchers at the University of Edinburgh are carrying out a survey on GLP-1 agonist (weight loss drug) use and pregnancy
If you provide care before, during or after pregnancy or are involved in the prescribing or GLP-1 agonists please consider taking part.
Survey link for healthcare professionals.
Please share widely with your networks and on social media. Both surveys have ethical approval from the Edinburgh Medical School Research Ethics Committee. Please note, ethics approval is not in place to recruit directly from NHS clinics so please do not post the advert in NHS clinics or on NHS websites.